Sotatercept for pulmonary arterial hypertension on background therapy: a systematic review and meta-analysis of randomized controlled trials.

ABSTRACT:

Background

Pulmonary arterial hypertension (PAH) is a progressive condition that leads to right ventricular failure and reduced survival. Sotatercept, a fusion protein targeting the activin signaling pathway, may offer disease-modifying benefits.

Objective

This study aimed to evaluate the efficacy and safety of sotatercept compared to placebo in adults with PAH receiving background therapy.

Methods

A systematic literature search was conducted through April 2025 to identify randomized controlled trials (RCTs) comparing sotatercept with placebo in PAH. Data were pooled using risk ratios (RR) or mean differences (MD) with 95% confidence intervals, analyzed using R software.

Results

Three RCTs including 601 patients were analyzed. Sotatercept significantly improved

SUBMITTER: Manasrah A 

PROVIDER: S-EPMC12671513 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature